Astella’s iota receives FDA go-ahead for bladder implant trial

Astellas Pharma subsidiary, iota Biosciences, has won an investigational device exemption (IDE) from the US Food and Drug Administration (FDA) to conduct a trial evaluating its implantable device for the treatment of underactive bladder.